AMD – Talk Bio

EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies

3 months ago talkbio0Tagged AMD, anti-VEGF therapy, Clinical Trials, DURAVYU, EyePoint Pharmaceuticals, Glycogen storage disease type II, Movement, Prices, vorolanib

DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement

Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations

4 months ago talkbio0Tagged AMD, Attitude, bevacizumab, biopharmaceutical company, cost-saving measures, Glycogen storage disease type II, Lytenava, restructuring, strategic

Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.

Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial

5 months ago talkbio0Tagged AMD, Approved, Attitude, Biologics License Application, Glycogen storage disease type II, Lytenava, New-onset refractory status epilepticus, United States Food and Drug Administration, Wet Age-Related Macular Degeneration

Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval

Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy

5 months ago talkbio0Tagged AMD, Attitude, Clinical Trials, Failure (biologic function), File (record), Glycogen storage disease type II, OTLK, Prices, United States Food and Drug Administration

Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing